Mibefradil, a T-type channel-selective calcium antagonist: Clinical trials in chronic stable angina pectoris

American Journal of Hypertension

Volumn 11, Issue 4 SUPPL. 2, 1998, Pages 95S-102S

  Massie, Barry M ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Angina pectoris; Calcium antagonist; Mibefradil; T type calcium channel

Indexed keywords

AMLODIPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DILTIAZEM; MIBEFRADIL; NITRATE;

ABDOMINAL PAIN; ADULT; AGED; ANGINA PECTORIS; CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; EXERCISE TOLERANCE; FEMALE; HEADACHE; HUMAN; LEG EDEMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; ST SEGMENT DEPRESSION; VERTIGO;

AMLODIPINE; ANGINA PECTORIS; BENZIMIDAZOLES; CALCIUM CHANNEL BLOCKERS; CHRONIC DISEASE; CLINICAL TRIALS; DILTIAZEM; HUMANS; MIBEFRADIL; TETRAHYDRONAPHTHALENES;

EID: 0031800773     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0895-7061(98)00006-5     Document Type: Article

References (31)

1. Carbajal E, Deedwania P: Contemporary approaches in medical management of patients with stable coronary artery disease. Med Clin North Am 1995;79:1063-1084.
2. Gorlin R: Treatment of chronic stable angina pectoris. Am J Cardiol 1992;70:26G-31G.
3. Abrams J: New insights into the management of myocardial ischemia: overview. Am Heart J 1990;120:719-721.
4. Amsterdam E: Rationale for intermittent nitrate therapy. Am J Cardiol 1992;70:55G-60G.
5. Subramanian V, Bowles M, Khurmi N, et al: Rationale for the choice of calcium antagonists in chronic stable angina: An objective double-blind placebo-controlled comparison of nifedipine and verapamil. Am J Cardiol 1982;50:1173-1179.
6. Frishman W, Charlap S, Kimmel B: Effects of diltiazem, nifedipine and their combination in transient ST-segment deviations on the ambulatory ECG in patients with stable angina pectoris. Circulation 1988;77:774-786.
7. The Danish Study Group on Verapamil in Myocardial Infarction: Secondary prevention with verapamil after myocardial infarction. Am J Cardiol 1990;66:331-401.
8. The Danish Study Group on Verapamil in Myocardial Infarction: Effect of verapamil on mortality and major events after acute myocardial infarction (The Danish Verapamil Infarction Trial II - DAVIT II). Am J Cardiol 1990;66:779-785.
9. Subramanian V, Bowles M, Davies A, Raftery E: Calcium channel blockade as primary therapy for stable angina pectoris: a double-blind placebo-controlled comparison of verapamil and propranolol. Am J Cardiol 1982;50:1158-1163.
10. Katz A: Calcium channel diversity in the cardiovascular system. J Am Coll Cardiol 1996;28:522-529.
11. Opie L: Calcium channel antagonists in the treatment of coronary artery disease fundamental pharmacological properties relevant to clinical use. Prog Cardiovasc Dis 1996;38:273-290.
12. Bean B: Two kinds of calcium channels in canine atrial cells: differences in kinetics, selectivity, and pharmacology. J Gen Physiol 1985;86:1-30.
13. Hagiwara N, Irisawa H, Kameyama M: Contribution of two types of calcium currents to the pacemaker potentials of rabbit sino-atrial node cells. J Physiol 1988;395: 233-253.
14. Beam K, Knudson C: Calcium currents in embryonic and neonatal mammalian skeletal muscle. J Gen Physiol 1988;91:781-798.
15. Bean B: Classes of calcium channels in vertebrate cells. Annu Rev Physiol 1989;51:367-384.
16. Argibay J, Fischmeister R, Hartzell H: Inactivation, reactivation and pacing dependence of calcium current in frog cardiocytes: correlation with current density. J Physiol (Lond) 1988;401:201-226.
17. Beuckelmann D, Näbauer M, Erdmann E: Characteristics of calcium-current in isolated human ventricular myocytes from patients with terminal heart failure. J Mol Cell Cardiol 1991;23:929-937.
18. Hirano Y, Fozzard H, January C: Characteristics of L-and T-type currents in canine cardiac Purkinje cells. Am J Physiol 1989;256:H1478-H1492.
19. 2+ currents in single canine Purkinje cells. Circ Res 1989;65:1735-1750.
20. 2+ channels by Ro 40-5967. Circ Res 1994;75:144-148.
21. 2+ channel in cardiac tissue. Eur J Pharmacol 1995;290:155-158.
22. Clozel J-P, Banken L, Osterrieder W: Effects of Ro 40-5967, a novel calcium antagonist, on myocardial function during ischemia induced by lowering coronary perfusion pressure in dogs: comparison with verapamil. J Cardiovasc Pharmacol 1989;14:713-721.
23. Mulder P, Richard V, Compagnon P, et al: Increased survival after long-term treatment with mibefradil, a selective T-channel calcium antagonist, in heart failure. J Am Coll Cardiol 1997;29:416-421.
24. Alpert J, Bakx A, Braun S, et al: The anti-anginal and anti-ischemic effects of mibefradil in the treatment of patients with chronic stable angina pectoris: placebo-controlled studies. Am J Cardiol 1997;80:20C-26C.
25. Alpert J, Kobrin I, DeQuattro V, et al: Additional anti-anginal and anti-ischemic efficacy of mibefradil in patients pretreated with a beta-blocker for chronic stable angina pectoris. Am J Cardiol 1997;79:1025-1030.
26. Bakx A, van der Wall E, Braun S, et al: Effects of the new calcium antagonist mibefradil (Ro 40-5967) on exercise duration in patients with chronic stable angina pectoris: a multicenter, placebo-controlled study. Am Heart J 1995;130:748-757.
27. Braun S, van der Wall E, Emanuelsson H, Kobrin I: Effects of a new calcium antagonist, mibefradil (Ro 40-5967), on silent ischemia in patients with stable chronic angina pectoris: a multicenter placebo-controlled study. J Am Coll Cardiol 1996;27:317-322.
28. Tzivoni D, Kadr H, Braat S, et al: Efficacy of mibefradil in comparison to amlodipine in suppressing exercise-induced and daily silent ischemia: results of a multicenter, placebo-controlled trial. Circulation 1997;96:2557-2564.
29. Davies G, Kobrin I, Caspi A, et al: Long-term anti-anginal and anti-ischemic effects of mibefradil, the novel T-type calcium channel blocker: a multicenter, double-blind, placebo-controlled, randomized comparison with diltiazem SR. Am Heart J 1997;134:220-228.
30. Aristizabel D, Frolich E: Calcium antagonists, in Singh B, Dzau V, Vanhoutte P, Woosley R (eds): Cardiovascular Pharmacology and Therapeutics. Churchill Livingstone Inc., New York, 1994, pp 185-202.
31. Davies GJ, Tzivoni D, Kobrin I: Mibefradil in the treatment of chronic stable angina pectoris: comparative studies with other calcium antagonists. Am J Cardiol 1997;80(4B):34C-39C.